Phosphoantigen-reactive Vγ9Vδ2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 858-861

  Poccia, Fabrizio ^a,b   Battistini, Luca ^c   Cipriani, Barbara ^c   Mancino, Giorgio ^a,b   Martini, Federico ^a   Gougeon, Marie Lise ^d   Colizzi, Vittorio ^a,b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; BACTERIAL ANTIGEN; GAG PROTEIN; HEMITERPENE; ISOPENTENYL DIPHOSPHATE; LYMPHOCYTE ANTIGEN RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1; ORGANOPHOSPHORUS COMPOUND; PHOSPHOPROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM; PHYSIOLOGY; VIROLOGY;

ANTIGENS, BACTERIAL; CELLS, CULTURED; CHEMOKINES, CC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMITERPENES; HIV CORE PROTEIN P24; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGE INFLAMMATORY PROTEIN-1; MYCOBACTERIUM; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHOPROTEINS; RANTES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 0033190539     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314925     Document Type: Article

References (15)

1. 1. Parker CM, Groh V, Band H, et al. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med 1990;171:1597-612.
2. 2. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of γδ T cells by nonpeptidic mycobacterial ligands. Science 1994;264:267-70.
3. 3. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 1995;375:155-8.
4. 4. Burk MR, Mori L, De Libero G. Human Vγ9Vδ2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. Eur J Immunol 1995;25:2052-8.
5. 5. Poccia F, Gougeon ML, Bonneville M, et al. Innate T cell immunity to nonpeptidic antigens and MHC class 1 recognition. Immunol Today 1998;19:253-6.
6. 6. Wallace M, Bartz SR, Chang WL, MacKenzie D, Pauza CD, Malkovsky M. γδ T lymphocytes' responses to human immunodeficiency virus. Clin Exp Immunol 1996;103:177-84.
7. 7. Bukowski JF, Morita CT, Brenner MB. Recognition and destruction of virus-infected cells by human γδ CTL. J Immunol 1994;153:5133-40.
8. 8. Wallace M, Malkovsky M, Carding SR. Gamma/delta T lymphocytes in viral infections. J Leukoc Biol 1995;58:277-83.
9. 9. Poccia F, Cipriani B, Vendetti S, et al. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive Vγ9Vδ2 T lymphocytes. J Immunol 1997;159:6009-17.
10. 10. Gan YH, Malkovsky M. Mechanisms of simian gamma delta T cell cytotoxicity against tumor and immunodeficiency virus-infected cells. Immunol Lett 1996;49:191-6.
11. 11. Poccia F, Boullier S, Lecoeur H, et al. Peripheral Vγ9/Vδ2 T cell deletion and anergy to non-peptidic mycobacterial antigens in asymptomatic HIV-1 infected persons. J Immunol 1996;157:449-61.
12. 12. Wallace M, Scharko AM, Pauza CD, et al. Functional γδ T cell defect associated with human immunodeficiency virus infection. Mol Med 1997; 3:60-71.
13. 13. Moore JP, Trkola A, Dragic T. Coreceptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-62.
14. + T cells. Science 1995;270:1811-5.
15. + T cells. Immunol Today 1996;17:217-24.